rapcabtagene autoleucel + rituximab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma, Diffuse
Conditions
Scleroderma, Diffuse
Trial Timeline
Oct 29, 2024 → Aug 30, 2032
NCT ID
NCT06655896About rapcabtagene autoleucel + rituximab
rapcabtagene autoleucel + rituximab is a phase 2 stage product being developed by Novartis for Scleroderma, Diffuse. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06655896. Target conditions include Scleroderma, Diffuse.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06655896 | Phase 2 | Recruiting |
Competing Products
15 competing products in Scleroderma, Diffuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| Fludarabine + Cyclophosphamide + Thymoglobulin | Amgen | Phase 1 | 32 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |